Cue Biopharma (CUE) Common Equity (2017 - 2025)
Cue Biopharma (CUE) posted Common Equity of $26.4 million for Q4 2025, up 99.55% sequentially from $13.2 million in Q3 2025, and up 51.05% YoY from $17.5 million in Q4 2024.
Cue Biopharma (CUE) Common Equity (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Common Equity for 9 years, with the latest figure at $26.4 million in Q4 2025.
- Quarterly Common Equity rose 51.05% year-over-year to $26.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.4 million (up 51.05% YoY) and the FY2025 annual result came in at $26.4 million, up 51.05% from the prior year.
- Common Equity rose to $26.4 million in Q4 2025 per CUE's latest filing, from $13.2 million in the prior quarter.
- Over five years, Common Equity peaked at $72.9 million in Q2 2021 and troughed at $6.6 million in Q1 2025.
- A 5-year average of $42.6 million and a median of $44.3 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity soared 54.01% in 2021, then slumped 78.09% in 2025.
- Over 5 years, Common Equity stood at $65.5 million in 2021, then rose by 0.29% to $65.7 million in 2022, then sank by 43.54% to $37.1 million in 2023, then sank by 52.81% to $17.5 million in 2024, then surged by 51.05% to $26.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $26.4 million, $13.2 million, and $18.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.43 Mn |
| Sep 30, 2025 | 13.25 Mn |
| Jun 30, 2025 | 18.16 Mn |
| Mar 31, 2025 | 6.58 Mn |
| Dec 31, 2024 | 17.50 Mn |
| Sep 30, 2024 | 25.37 Mn |
| Jun 30, 2024 | 21.62 Mn |
| Mar 31, 2024 | 30.04 Mn |
| Dec 31, 2023 | 37.09 Mn |
| Sep 30, 2023 | 42.67 Mn |
| Jun 30, 2023 | 46.00 Mn |
| Mar 31, 2023 | 55.02 Mn |
| Dec 31, 2022 | 65.68 Mn |
| Sep 30, 2022 | 50.76 Mn |
| Jun 30, 2022 | 59.76 Mn |
| Mar 31, 2022 | 64.67 Mn |
| Dec 31, 2021 | 65.49 Mn |
| Sep 30, 2021 | 63.52 Mn |
| Jun 30, 2021 | 72.91 Mn |
| Mar 31, 2021 | 69.67 Mn |